Innovative NeuroTechonologies, Inc. (INT) focuses on the development of novel biologics for the treatment of Alzheimer’s disease (AD) and other related human tauopathies, such as frontotemporal dementia (FTD or Pick’s disease) and chronic traumatic encephalopathy (CTE).  INT is currently in the process advancing multiple monoclonal antibody (mAb) candidates against key epitopes of Tau, which are centrally involved in the early conversion of "normal" physiologic Tau to "pathological" Tau, into Phase I clinical trials within the next three to four years as prospective passive immunotherapies for these neurodegenerative conditions.